Consistent with the proposed apoptotic mechanism of BTZ cytotoxicity in NSCLC cells, IHC staining of the treated tumors for cleaved caspase-3 revealed strong staining (20%–40% of nuclei positive) in tumors exposed to BTZ/navitoclax/carboplatin combination treatment versus vehicle (Supplementary Fig. S6A and S6B). The gene discussed is CASP3; the disease is non-small cell lung carcinoma.